|
RPF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.67488245494951E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.91884352430361E-12 |
| Normal-vs-Stage2 |
1.06899999963161E-07 |
| Normal-vs-Stage3 |
3.530509218308E-14 |
| Normal-vs-Stage4 |
1.84074977482851E-12 |
| Stage1-vs-Stage2 |
4.491200E-01 |
| Stage1-vs-Stage3 |
1.759570E-02 |
| Stage1-vs-Stage4 |
1.042200E-02 |
| Stage2-vs-Stage3 |
3.811000E-01 |
| Stage2-vs-Stage4 |
2.622000E-01 |
| Stage3-vs-Stage4 |
7.130800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.99680288865056E-15 |
| Normal-vs-AfricanAmerican |
1.151420E-04 |
| Normal-vs-Asian |
1.12189999956769E-07 |
| Caucasian-vs-AfricanAmerican |
2.257200E-01 |
| Caucasian-vs-Asian |
2.136800E-01 |
| AfricanAmerican-vs-Asian |
7.968000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.5527136788005E-15 |
| Normal-vs-Female |
2.56306087464964E-12 |
| Male-vs-Female |
2.792400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.74840150638056E-11 |
| Normal-vs-Age(41-60Yrs) |
4.65738558830253E-13 |
| Normal-vs-Age(61-80Yrs) |
1.01363362148277E-13 |
| Normal-vs-Age(81-100Yrs) |
3.38249999998208E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.902000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.361900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.456800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.345800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.026000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.855800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.050200E-02 |
| Classical-VS-Follicular |
6.588000E-01 |
| Classical-VS-Other |
3.537600E-01 |
| Classical-VS-Normal |
2.37965203098156E-12 |
| Tall-VS-Follicular |
5.098300E-02 |
| Tall-VS-Other |
9.753600E-01 |
| Tall-VS-Normal |
1.75679470970636E-11 |
| Follicular-VS-Other |
4.323400E-01 |
| Follicular-VS-Normal |
2.07899999993266E-07 |
| Other-VS-Normal |
1.844510E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.38729044813135E-13 |
| Normal-vs-N1 |
3.84839937694892E-11 |
| N0-vs-N1 |
1.570170E-01 |
|
|
